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Summary
Context: The hypothalamic-pituitary-adrenal (HPA) axis is one of the body’s main systems that
controls response to stress. It acts through the hormone cortisol. While the dysregulation of
cortisol has been associated with anxiety disorders, the evidence is inconsistent. Moreover, only a
few small studies have assessed this relationship in older adults.
Objective: To determine whether in adults aged 65 years and over there is a difference in daily
cortisol pattern between those with and without an anxiety disorder.
Methods: The study population comprised 1788 older adults from a population-based cohort. The
Munich version of the Composite International Diagnostic Interview was used to diagnose anxiety
disorders (generalized anxiety disorder, social phobia, specific phobia, agoraphobia and panic
disorder). The cortisol awakening response and total cortisol secretion over the day were
calculated from cortisol levels in four saliva samples taken over the course of one day
(at awakening, 30 min after awakening, at 1700 h, at bedtime).
Results: Older adults with an anxiety disorder (n = 145, median duration since first symptoms 41
years) had a lower cortisol awakening response ( p = 0.02) than those without such a disorder
(n = 1643). This association was most prominent in those with generalized anxiety disorder
( p = 0.008), but was not associated with the extent of chronicity of anxiety disorders.
Conclusion: Older adults from the general population with long-lasting anxiety disorders had a
lower cortisol awakening response than those without. This is consistent with the notion that
chronic anxiety may result in downregulation of HPA-axis activity. Longitudinal studies are needed
to confirm this mechanism.
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The hypothalamic-pituitary-adrenal axis (HPA axis) is one of
the body’s main systems that controls response to stress. It
acts through the hormone cortisol, which is produced in the
adrenal cortex and affects many tissues including the brain.
Cortisol is secreted in a distinct daily pattern whereby corti-
sol levels rise rapidly after awakening (the cortisol awakening
response or CAR) and decrease slowly thereafter. Deregula-
tion of the CAR, and total cortisol secretion over the day have
been associated with various disorders, including anxiety
disorders (Vreeburg et al., 2010). In addition, age-dependent
HPA-axis dysregulation may increase the vulnerability of
older adults for psychiatric disorders (Van Cauter et al.,
1996).
Although numerous studies have described the relation-
ship between the HPA axis and anxiety disorders, the evi-
dence is inconsistent and only a few studies assessed this
relationship in older adults. While one study reported that
older adults (mean age 74, n = 111) with generalized anxiety
disorder (GAD) had higher cortisol levels than those without
GAD (Mantella et al., 2008), another study (mean age 76,
n = 48) reported no association of cortisol levels with an
anxiety symptom score (Heaney et al., 2010). A further study
of older people (mean age 73, n = 201) also reported no
difference in total cortisol levels during the day between
people with and without lifetime GAD in a non-stressful
condition, but the CAR was not assessed (Chaudieu et al.,
2008).
In the current study we assessed not only total cortisol
secretion, but also the CAR. We jointly analyzed anxiety
disorders, but also present data on GAD, social phobia,
specific phobia and agoraphobia separately. Furthermore,
this study was no convenience sample, but comprised older
adults (aged 65 and over) from the general population to
minimize selection effects.
2. Methods
2.1. Study setting
This study was set in the Rotterdam Study, a prospective
population-based cohort study of older adults designed to
assess risk factors for chronic diseases (Hofman et al., 2011).
In 1990, all residents in a district in Rotterdam who were
aged 55 years and over were invited to participate. Every
four years, participants undergo an extensive home inter-
view and physical examination at a research center. The
Medical Ethics Committee of the Erasmus MC approved the
Rotterdam Study.
The fourth examination round (2002—2004, n = 3550)
assessed anxiety disorders and salivary cortisol levels. The
study population comprised 1788 people after exclusion of
people without a valid anxiety assessment (n = 287), people
without the first two cortisol measurements (n = 1152), peo-
ple using corticosteroids (n = 287), and people with dementia
(n = 36). Almost two thirds of those who were excluded
(n = 1762) were female against 56.9% of the study partici-
pants. The excluded group was significantly older than the
study population (mean age 77.3 versus 74.7) and had a lower
education.2.2. Assessment of anxiety disorders
Prevalent anxiety disorders were diagnosed during the home
interview. Trained lay interviewers conducted a slightly
adapted version of the Munich version of the Composite
International Diagnostic Interview (M-CIDI, Wittchen et al.,
1998). The following anxiety disorders were assessed with a
computerized diagnostic algorithm according to DSM-IV cri-
teria: GAD, panic disorder, agoraphobia, social phobia and
specific phobia. Age of symptom onset was recorded. Obses-
sive compulsive disorder and post-traumatic stress disorder
(PTSD) were not assessed, because these disorders are rela-
tively rare in the general population.
2.3. Salivary cortisol protocol
Saliva samples were collected on awakening (T1), 30 min
after awakening (T2), at 1700 h (T3), and at bedtime (T4).
Cortisol levels in these samples were determined as pre-
viously described (Dekker et al., 2008). The multiple mea-
sures of cortisol were combined in summary measures to
provide valid information about the diurnal pattern of corti-
sol. We calculated the area under the curve with respect to
the ground (AUCg) and the cortisol awakening response
(CAR). The AUCg summarizes overall diurnal cortisol expo-
sure. The CAR is a measure of the dynamics of the HPA-axis
response upon awakening. The CAR and the AUCg are thought
to be regulated differently (Clow et al., 2004). The AUCg was
calculated as the total area under the curve from the indi-
vidual cortisol measures on the Y-axis and the time between
cortisol measures on the X-axis. To not measure the effect of
the CAR, we did not include T2 in the calculation. We
corrected for total time awake and only calculated the AUCg
for those with data on all three time points (n = 1664). The
CAR was calculated as the difference between cortisol levels
at T2 and T1 over two (n = 1788, Pruessner et al., 2003).
Analyses on the CAR were adjusted for the time between
measurements.
2.4. Assessment of other variables
Age, sex, marital status, psycholeptics use, psychoanaleptics
use, hormonal drug use, usual sleep duration, and alcohol,
coffee and tea consumption were recorded. Education was
grouped according to the Standard Classification of Education
and rated on a scale from primary education (1) to university
level (7). Height and weight were measured at the research
center to calculate body mass index (BMI). Smoking was
coded according to current smoking status. Cognitive capa-
city was assessed using the Mini Mental State Examination. A
cut-off of 26 indicated adequate cognitive capacity versus
impaired cognitive capacity. Disability (Activities of Daily
Living) was assessed with the Stanford Health Assessment
Questionnaire. The standard cut-off of a mean score of 0.5
indicated no disability versus mild to severe disability. Parti-
cipants were continuously monitored for occurrence of cor-
onary heart disease. International Classification of Diseases,
10th Revision was used to assign diagnoses of myocardial
infarction (I21), percutaneous transluminal coronary angio-
plasty, coronary artery bypass graft and other forms of
acute (I24) or chronic ischemic heart disease (I25). Diabetes
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was at least 7.0 mmol/l, a non-fasting plasma glucose level
was at least 11.1 mmol/l, or oral antidiabetes medication or
insulin were used, or treated by diet and registered by the
general practitioner (GP) as having diabetes. The number of
sites with atherosclerotic plaques was identified by ultra-
sonography of both carotid arteries. Blood pressure was
measured at the right brachial artery using a random-zero
sphygmomanometer with the participant in sitting position.
In those who screened positive for depressive symptoms
with the Center for Epidemiological Studies Depression scale
(CES-D, cut-off score of 16), DSM-IV-defined major depression
was assessed with a semi-structured clinical interview (Sche-
dules for Clinical Assessment of Neuropsychiatry). The CES-D
has a high sensitivity for major depression in older adults
(Beekman et al., 1997). Depressive syndromes during fol-
low-up were assessed based on two clinical interviews, self-
report depression and GP records. Month of cortisol sampling
was categorized in months with less daylight (October—Feb-
ruary) and months with more daylight (March—September). All
variables, except education, were assessed during the same
examination round as anxiety disorders and salivary cortisol.
2.5. Statistical analysis
Baseline characteristics for persons with and without anxiety
disorder were compared using chi-square statistics, Student’s
t-tests and the Mann—Whitney U test. AUCg and CAR were
normally distributed after excluding values above the 99th
percentile. Covariates were imputed using the Expectation—
Maximization algorithm. All covariates had less than 2% missing
values. Differences in AUCg and CAR in persons with and
without anxiety disorders were tested using linear regression
analyses. Covariates were selected if the effect estimates of
the association between cortisol levels and anxiety disorders
changed more than 5% in the models. Subtypes of anxiety
disorders were analyzed jointly and separately with the excep-
tion of panic disorder which was too infrequent. We repeated
all analyses excluding people with major depression. Data
were analyzed using SPSS PASW version 17.
3. Results
The study population comprised 145 people with an anxiety
disorder and 1643 people without an anxiety disorder. Agor-
aphobia (n = 71, 3.9%) and GAD (n = 39, 2.1%) were the most
prevalent anxiety disorders. Thirty-five people were diag-
nosed with specific phobia (1.9%), sixteen had social phobia
(0.9%) and four had a panic disorder (0.3%). Sixteen people
(0.9%) had more than one anxiety disorder. The character-
istics of the study population are shown in Table 1. The group
with anxiety disorders comprised more females than the
group without such a disorder (81% vs. 55%, p < 0.001). In
addition, those with an anxiety disorder had a lower educa-
tion ( p = 0.003) and an eight-fold higher prevalence of
depression than those without an anxiety disorder (8% vs.
1%, p < 0.001).
Unadjusted cortisol levels at 30 min after awakening and at
1700 h were lower in people with anxiety disorders. Supple-
mentary Fig. 1 shows the cortisol pattern over the day of older
adults with and without anxiety disorders. After adjustmentfor covariates, cortisol level at 30 min after awakening was
lower in those with an anxiety disorder (beta = 2.67;
95%CI = 4.44, 0.90; p = 0.003), but not cortisol level at
awakening (beta = 0.28; 95%CI = 1.79, 1.23; p = 0.72), at
1700 h (beta = 0.47; 95%CI = 1.06, 0.12; p = 0.13) or at bed
time (beta = 0.18; 95%CI = 0.63, 0.28; p = 0.44). In addi-
tion, those with an anxiety disorder had significantly lower CAR
than those without an anxiety disorder (beta = 1.19;
p = 0.02, Table 2). Total cortisol secretion did not differ. When
anxiety disorders were stratified by subtype, the association
between GAD and the CAR was significant (beta = 2.50;
p = 0.008, Table 2). Exclusion of people with major depression
did not change these results (all anxiety disorders:
beta = 1.18; 95%CI = 2.17, 0.18; p = 0.021, GAD:
beta = 2.58; 95%CI = 4.66, 0.50; p = 0.015).
In a post hoc analysis we tested the influence of chronicity
of the anxiety disorders on the CAR by comparing the CAR of
people with an anxiety disorder with duration shorter than
5.44 years (lowest quartile) to those with an anxiety disorder
that lasted longer than 59.69 years (highest quartile). The
groups did not differ significantly, but, if anything, the people
with a more chronic anxiety disorder had a higher CAR
(beta = 2.52; 95%CI = 0.86, 5.90; p = 0.14).
4. Discussion
In this population-based study of older adults, people with an
anxiety disorder had a significantly lower CAR than those
without anxiety disorder.
Three previous studies assessed the association between
anxiety and cortisol levels in older adults. First, Mantella
et al. (2008) found higher cortisol levels (CAR as well as total
cortisol secretion) in people with GAD than in healthy con-
trols. This is opposite to our finding and may result from
recruitment differences. Mantella et al. used a convenience
sample recruited via e.g. advertisements and mental health
clinician referral that likely included more acute and help-
seeking cases while we used a population-based sample with
prevalent and chronic cases. Second, Heaney et al. (2010) did
not find a difference in cortisol levels between older adults
with and without anxiety. While our study included 145
people with anxiety disorders, the study of Heaney et al.
comprised 25 older people with anxiety symptoms. This study
may not have had enough power to detect small differences
in cortisol levels. Third, Chaudieu et al. (2008) assessed total
cortisol secretion and not the CAR in a population-based
setting. They observed no difference in cortisol secretion
between people with and without lifetime GAD in non-stress-
ful conditions, which is compatible with our finding.
In the largest study of anxiety and cortisol in adults (age
range 18—65), Vreeburg et al. (2010) observed a higher CAR in
people with anxiety disorders. This population was largely
recruited from GPs and specialized mental health care insti-
tutions. Consequently, the study comprised many acute,
help-seeking cases, whereas we included only prevalent,
chronic anxiety cases from the general population. This
difference is also reflected in the higher comorbidity of major
depression (77.8%) and a higher prevalence of panic disorder
cases (59.4%) in the sample of Vreeburg et al. Furthermore,
the high CAR was driven by those with a panic disorder with
agoraphobia and by those with a comorbid depression.
Table 1 Characteristics of the study group.
Anxiety disorder* No anxiety disorder p **
(n = 145) (n = 1643)
% Women 80.7 54.8 <0.001
Age, years, mean (SD; range) 74.7 (5.3; 66.1—90.0) 74.7 (5.6; 65.1—92.7) 0.93
BMI, kg/m2, mean (SD; range) 27.7 (4.2; 18.6—41.3) 27.5 (4.0; 14.2—45.7) 0.44
% Current smokers 53.8 58.5 0.29
Alcohol drinking, units/day, median (IQR; range) 0.1 (1.0; 0—4.7) 0.5 (1.2; 0—5.0) <0.001
Coffee drinking, cups/day, median (IQR; range) 3.0 (2.0; 0—23) 3.0 (2.0; 0—24) 0.14
Tea drinking, cups/day, median (IQR; range) 3.0 (2.1; 0—12) 3.0 (3.0; 0—16) 0.64
Mean sleep duration, hours, mean (SD; range) 6.5 (1.5; 2.5—10) 6.9 (1.2; 2—11) 0.013
Education, mean (SD; range) 2.6 (1.5; 1—6) 3.1 (1.7; 1—7) 0.003
Marital status 0.68
% single 4.1 5.2
% married 60.7 64.5
% widowed 29.0 25.3
% divorced 6.2 5.2
Cognitive status (MMSE), mean (SD; range) 27.4 (1.8; 19.0—30.0) 27.7 (1.8; 17.0—30.0) 0.09
% Impaired cognitive capacity 14.5 9.0 0.04
Functional disability, median (IQR; range) 0.6 (0.7; 0—2.3) 0.3 (0.5; 0—2.8) <0.001
% Mild to severe functional disability 64.8 39.0 <0.001
% Major depression 8.3 1.1 <0.001
% Depression during follow-up 46.2 25.6 <0.001
Depressive symptoms (CES-D), median (IQR; range) 9.0 (16.1; 0.0—48.0) 3.0 (6.0; 0.0—44.0) <0.001
Negative affect (CES-D), median (IQR; range)
Anxiety duration, years, median (IQR; range) 2.0 (7.0; 0.0—20.0) 0.0 (1.0; 0.0—16.0) <0.001
% Psycholeptics users 40.6 (54.4; 0.3—73.2) — —
% Psychoanaleptics users 25.5 12.4 <0.001
% Hormonal medication users 9.7 3.6 <0.001
2.1 1.2 0.34
% Diabetes Mellitus 13.1 17.7 0.16
% Coronary Heart Disease 4.8 8.5 0.12
Systolic blood pressure, mean (SD; range) 156.6 (22.6; 106.0—217.0) 152.4 (21.3; 99.5—240.0) 0.02
No. of atherosclerotic plaques, mean (SD; range) 2.7 (1.8; 0—6) 2.9 (1.9; 0—6) 0.13
Cortisol levels, nmol/l, mean (SD; range)
T1, at awakening 14.1 (7.7; 0.3—35.1) 14.7 (8.6; 0.0—60.6) 0.40
T2, 30 min after awakening 15.9 (8.3; 0.2—41.9) 18.4 (10.2; 0.1—64.2) 0.001
T3, 1700 h 3.7 (2.4; 0.4—13.7) 4.2 (3.4; 0.0—29.3) 0.012
T4, at bedtime 2.2 (3.1; 0.1—26.7) 2.3 (2.4; 0.0—24.3) 0.71
AUCg 6.5 (3.0; 0.3—17.2) 7.0 (3.4; 0.4-26.3) 0.12
CAR 0.9 (5.1; 15.6—14.3) 1.8 (5.5; 27.0—28.0) 0.05
Time of the first sample, mean (SD; range) 0731 h (48 min; 0425—0941 h) 0734 h (55 min; 0305—1245 h) 0.60
% Sampling in months with more daylight 58.6 52.5 0.16
Abbreviations: AUCg, area under the curve with respect to the ground; BMI, body mass index; CAR, cortisol awakening response; CES-D,
Center for Epidemiological Studies Depression scale; IQR, inter quartile range; MMSE, mini mental state examination; SD, standard
deviation.
* The group of anxiety disorders comprised people with agoraphobia, social phobia, specific phobia, panic disorder and generalized anxiety
disorder.
** t-tests, chi square tests or Mann—Whitney U tests were applied to test for difference.
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HPA axis, raising total cortisol levels and leading to a higher
CAR. However, it has been hypothesized that the HPA axis
reacts to stress with temporal hyperactivity, but when stress
persists the HPA axis becomes hypoactive (Fries et al., 2005).
This mechanism has also been observed for depression.
Oldehinkel et al. (2001) observed lower urinary cortisol
levels in chronically depressed older adults, not in more
acutely depressed people. Thus while cortisol may be
raised during acute anxiety, the HPA axis reacts to a chronicdisorder with reduced cortisol levels. This change from
hyperactivity of the HPA axis to hypoactivity is likely
mediated through increased sensitivity to negative feed-
back from circulating cortisol (Houshyar et al., 2001). In our
study, we observed no association between extent of chroni-
city of the anxiety disorder and cortisol levels. However,
acute and recent onset cases are rare in community-dwelling
older adults, and even the group with the shortest duration
of symptoms (lowest quartile) had an average duration of
more than 3 years.
Table 2 Associations between anxiety disorders and cortisol summary measures.
Cortisol summary measures
Area under the curve (AUCg) Cortisol awakening response (CAR)
n Beta (95%CI) p n Beta (95%CI) p
No anxiety disorder 1533 Reference 1643 Reference
All anxiety disorders * 131 0.39 (1.02, 0.24) 0.23 145 1.19 (2.15, 0.23) 0.02
Subtypes of anxiety disorders **
GAD 36 0.02 (1.22, 1.18) 0.97 39 2.50 (4.34, 0.65) 0.008
Social phobia 15 0.68 (1.10, 2.44) 0.46 16 1.48 (4.19, 1.24) 0.29
Specific phobia 31 1.26 (2.48, 0.03) 0.04 35 1.14 (2.98, 0.70) 0.22
Agoraphobia 63 0.62 (1.48, 0.25) 0.16 71 0.30 (1.60, 1.01) 0.66
Abbreviations: CI, confidence interval; GAD, generalized anxiety disorder.
All analyses were adjusted for age, gender, education, time of the first sample, months with more daylight, psychoanaleptic drug use, total
sleep duration, disability (yes/no), major depression, logarithm of negative affect sum score. Analyses of the CAR were additionally
adjusted for the time between the first and the second sample.
* All anxiety disorders comprised GAD, social phobia, specific phobia, agoraphobia and panic disorder.
** As some people have comorbid anxiety disorders, the numbers for GAD, social phobia, specific phobia and agoraphobia do not add up to
the number for all anxiety disorders. The number of panic disorders was too low to assess separately. In bold: p-values that are significant at
the 0.05 level.
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and subtypes of anxiety disorders. A lower CAR was observed
for all subtypes, but only GAD was significantly associated
with a lower CAR. This could not be attributed to impaired
cognitive capacity or depression comorbidity. GAD is gener-
ally characterized by a chronic course and is closely related
to depression for which similar findings were reported (Old-
ehinkel et al., 2001).
Older people are known to have a lower CAR (Kudielka and
Kirschbaum, 2003; Heaney et al., 2010). The exact function
of the CAR is unknown, but it has been suggested to play a
role in e.g. memory function, and the immune system. A low
CAR has been associated with cardiovascular and auto-
immune disorders (Kudielka and Kirschbaum, 2003), which
in turn have been linked to anxiety disorders (Strine et al.,
2008). Older adults with (chronic) anxiety disorders may thus
have an increased vulnerability to a wide range of disorders.
Our findings need to be discussed in light of some limita-
tions. First, non-compliance to the cortisol sampling proto-
col could explain the observed lower CAR, if more common in
those with anxiety disorders (Kudielka et al., 2003; Kudielka
and Kirschbaum, 2003). Second, cortisol samples were col-
lected on only one day. This may have resulted in less precise
estimates and reduced study power. Third, because this
study was performed in a population-based setting, our
results cannot easily be generalized to a clinical patient
group. Fourth, we did not assess PTSD or traumatic experi-
ences, which are associated with blunted cortisol levels.
However, PTSD has a relatively low prevalence and this
effect is therefore not likely to explain our findings. Fifth,
information on any remitted anxiety disorders or parental
history was not available. Last, because this study was cross-
sectional, we could not infer the causality of the associations
we observed.
In conclusion, older adults with an anxiety disorder in this
population-based study had a lower CAR than those without
such a disorder. This is compatible with the notion that
chronic anxiety may result in down regulation of HPA-axisactivity. Longitudinal studies are needed to confirm this
mechanism.
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